Risk increased for attention-deficit/hyperactivity disorder, autism spectrum disorder, and intellectual disability
Single low-dose esketamine reduces depressive episodes at 42 days postpartum for mothers with prenatal depression
Psychiatric comorbidities and familial confounding only partially explain this bidirectional association
93.3 percent increase seen from 2008 to 2020 among privately insured people, with faster growth in 2015 to 2020 than 2008 to 2014
Reduction seen in odds of major depressive episode, moderate-to-severe anxiety with intervention sessions delivered by nonspecialist
Hair cortisol concentrations, but not composite stress, anxiety, and depression scores, predicted birth complications
Findings seen for amphetamine/dextroamphetamine and methylphenidate exposure
Exposure during pregnancy, especially during the second trimester, is linked to later problems
Buprenorphine associated with lower risk for malformations, cardiac malformations, oral clefts, and clubfoot
Bidirectional association more pronounced among women without psychiatric comorbidities, strongest for multiple sclerosis